Waystar Considers Sale Amidst Declining Market Value

Waystar, a prominent healthcare software provider, is exploring strategic options, including a potential sale, according to sources familiar with the matter. The company, known for its technology that automates administrative tasks for hospitals and doctors, has engaged investment bank Evercore to advise on the process. This development comes two years after Waystar's public listing on the New York Stock Exchange.

Market Challenges Prompt Strategic Review

Waystar's decision to explore a sale is partly driven by a significant decline in its market value. The company's shares have fallen by 24% this year, reducing its market capitalization to approximately $4.8 billion. This decrease mirrors a broader downturn in the software sector, which has faced investor skepticism due to concerns over the impact of artificial intelligence on traditional software models.

Initially, Waystar positioned itself as a technology company to attract higher valuations typically associated with tech firms. This strategy helped the company's stock rise from $20 to a peak of $45 in 2025. However, market conditions have since shifted, pressuring the stock price and prompting the current strategic review.

Background and Major Stakeholders

Waystar was formed in 2017 through the merger of healthcare revenue management companies Zirmed and Navicure. The company went public in 2024, backed by major investors including EQT, the Canada Pension Plan Investment Board (CPPIB), and Bain Capital. Presently, EQT holds a 13% stake, CPPIB 10%, and BlackRock Institutional Trust Company 8%, according to data from LSEG.

Despite the potential sale, sources caution that discussions are in early stages and no definitive outcome is guaranteed. The company, along with its advisors, is assessing market interest and investor appetite for a transaction.

Industry Implications

Waystar's exploration of a sale highlights the challenges facing healthcare software companies amid evolving technological landscapes. As investors weigh the potential impacts of AI and other innovations, companies like Waystar must adapt to maintain competitiveness and valuation.

Neither Waystar nor Evercore has commented on the potential sale, and major stakeholders have also remained tight-lipped. The outcome of this strategic review could signal broader trends in the healthcare software market, particularly as companies navigate technological advancements and investor expectations.